Abstract
Background: Omalizumab is prescribed as a step-up therapy for patients with moderate to severe allergic asthma uncontrolled on high-dose inhaled corticosteroids and long acting beta agonists. However, hypersensitivity reactions may lead to its discontinuation and subsequent worsening or loss of asthma control. No successful desensitization protocols to omalizumab have been previously reported.
Objective: We aimed to determine the efficacy and safety of a novel one-day outpatient omalizumab desensitization protocol for patients with hypersensitivity reactions to omalizumab.
Methods: We retrospectively assessed the efficacy of omalizumab desensitization protocol performed in a university allergy-immunology clinic from July 2009 to July 2010.
Results: We successfully desensitized 3 patients with moderate-severe asthma to omalizumab. After desensitization all patients had improvement in asthma control and were able to discontinue or decrease chronic systemic steroid therapy.
Conclusions: This novel outpatient omalizumab desensitization protocol was a safe and effective approach for the treatment of omalizumab hypersensitivity in patients with moderate to severe allergic asthma who required omalizumab therapy.
Keywords: Asthma, omalizumab, hypersensitivity, desensitization, IgG1 monoclonal antibody, LABA therapy
Current Drug Safety
Title: Successful Desensitization of Three Patients with Hypersensitivity Reactions to Omalizumab
Volume: 6 Issue: 5
Author(s): Gregory Owens and Andrej Petrov
Affiliation:
Keywords: Asthma, omalizumab, hypersensitivity, desensitization, IgG1 monoclonal antibody, LABA therapy
Abstract: Background: Omalizumab is prescribed as a step-up therapy for patients with moderate to severe allergic asthma uncontrolled on high-dose inhaled corticosteroids and long acting beta agonists. However, hypersensitivity reactions may lead to its discontinuation and subsequent worsening or loss of asthma control. No successful desensitization protocols to omalizumab have been previously reported.
Objective: We aimed to determine the efficacy and safety of a novel one-day outpatient omalizumab desensitization protocol for patients with hypersensitivity reactions to omalizumab.
Methods: We retrospectively assessed the efficacy of omalizumab desensitization protocol performed in a university allergy-immunology clinic from July 2009 to July 2010.
Results: We successfully desensitized 3 patients with moderate-severe asthma to omalizumab. After desensitization all patients had improvement in asthma control and were able to discontinue or decrease chronic systemic steroid therapy.
Conclusions: This novel outpatient omalizumab desensitization protocol was a safe and effective approach for the treatment of omalizumab hypersensitivity in patients with moderate to severe allergic asthma who required omalizumab therapy.
Export Options
About this article
Cite this article as:
Owens Gregory and Petrov Andrej, Successful Desensitization of Three Patients with Hypersensitivity Reactions to Omalizumab, Current Drug Safety 2011; 6 (5) . https://dx.doi.org/10.2174/157488611798918692
DOI https://dx.doi.org/10.2174/157488611798918692 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Beneficial Effects and Therapeutic Promises of Diterpenes on Respiratory System
Current Respiratory Medicine Reviews Pharmacogenetics in Laboratory Diagnostics
Current Pharmacogenomics and Personalized Medicine Statistical Analysis, Optimization, and Prioritization of Virtual Screening Parameters for Zinc Enzymes Including the Anthrax Toxin Lethal Factor
Current Topics in Medicinal Chemistry Peptide Sequence Prediction Supported by Correlation-Associated Networks in Human Cerebrospinal Fluid
Combinatorial Chemistry & High Throughput Screening Computational Approach to the Discovery of Phytochemical Molecules with Therapeutic Potential Targets to the PKCZ protein
Letters in Drug Design & Discovery The Adenosine A2b Receptor: Its Role in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Predictive Genomics DNA Profiling for Athletic Performance
Recent Patents on DNA & Gene Sequences Pneumococcal Infections at Hajj: Current Knowledge Gaps
Infectious Disorders - Drug Targets Scaffolds for Blocking Protein-Protein Interactions
Current Topics in Medicinal Chemistry Tumor Markers in Patients with Benign and Malignant Pulmonary Diseases; Competitive Evaluation of ProGRP, NSE and Cyfra 21-1
Recent Patents on Biomarkers Proteases as Anti-Cancer Targets - Molecular and Biological Basis for Development of Inhibitor-Like Drugs Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Advances in Noninvasive Pulmonary Gene Therapy
Current Drug Delivery A2B Receptor Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry Defective Autophagy in Fibroblasts May Contribute to Fibrogenesis in Autoimmune Processes
Current Pharmaceutical Design Pulmonary Drug Delivery System: A Novel Approach for Drug Delivery
Current Drug Therapy The Complex Airway in Childhood Asthma
Current Pediatric Reviews Treating COPD in Older and Oldest Old Patients
Current Pharmaceutical Design Anesthesia for Bronchoscopy
Current Pharmaceutical Design Hydroxamate, a Key Pharmacophore Exhibiting a Wide Range of Biological Activities
Mini-Reviews in Medicinal Chemistry Functional Characteristic of Snake Venom Disintegrins: Potential Therapeutic Implication
Current Pharmaceutical Design